Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT836

Cell therapy (CAR-T) · Kills target cells, directed at MICA/MICB (MHC class I polypeptide-related sequences A and B), alpha 3 domain · developed by Fate Therapeutics

Phase 1 Most advanced trial
FATE Developer
1 Registered trials

What is FT836?

FT836 is an allogeneic, off-the-shelf T-cell product derived from clonal iPSCs and engineered with a chimeric antigen receptor that binds the alpha 3 domain of MICA and MICB, stress-induced NKG2D ligands expressed on many cancer cells. It also carries an alloimmune defense receptor targeting CD137 and a CD58 knockout. It is being studied in non-small cell lung, colorectal, breast, ovarian and endometrial cancers and head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
MICA/MICB (MHC class I polypeptide-related sequences A and B), alpha 3 domain (antigen), NKG2D ligands MICA and MICB (KLRK1) (binding partner it blocks), CD137 (4-1BB) (TNFRSF9) (secondary target)
Mechanism
Kills target cells, directed at MICA/MICB (MHC class I polypeptide-related sequences A and B), alpha 3 domain
Pathways
T-cell-mediated tumor cell lysis, evasion of NKG2D-mediated immunity by MICA/MICB shedding
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07216105 Phase 1 Non-Small Cell Lung Cancer Recruiting FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerColorectal CancerEndometrial CarcinomaHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerOvarian Cancer

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT836

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.